The Company expects that the restructuring activities will extend the cash runway into mid-2026. The Company ended the fourth quarter of 2023 with approximately $170.8M in cash, cash equivalents and investments. The Company’s outlook for 2024 cash, cash equivalents and investments is as follows: Cash, cash equivalents and investments at year end 2023 is $171M
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALLK:
- Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Allakos presents preclinical data on AK006 at AAAAI meeting
- Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
- ALLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Allakos Inc Reveals Breakthrough AK006 Data in Allergy Journal
